Biohaven is advancing its novel MoDE and TRAP extracellular protein degradation platforms into two pivotal studies—BHV-1300 for Graves' disease and BHV-1400 for IgA nephropathy. Late-stage programs include a pivotal epilepsy program with opakalim, with expected topline results in H2 2026, and a Phase 2 obesity study with taldefgrobep alfa, with topline data expected in H2 2026.
Cyborg Score Rationale
Biohaven maintains strong liquidity with $351.8M in cash as of March 31, 2026, while Q1 2026 R&D expenses were $103.8M. Multiple pivotal trial initiations and topline readouts are expected in H2 2026, representing substantial near-term value catalysts. The diverse pipeline spanning four therapeutic areas with proprietary degrader platforms provides strategic optionality.
Top Insights
Two pivotal program initiations expected mid-2026 for novel degrader platform (BHV-1300 in Graves' disease, BHV-1400 in IgA nephropathy)
Phase 2 obesity program (taldefgrobep alfa) completed enrollment; topline results expected in H2 2026 in large obesity market
Q1 2026 R&D expenses reduced to $103.8M from $187.6M prior year, indicating operational discipline and extended cash runway
Analyst coverage upgraded in May 2026 with price targets ranging $17–$30, suggesting significant upside potential
Named Competitors
Rare genetic and neurology programs — Gene therapy for rare CNS disorders
Rare genetic programs — Gene editing for rare genetic diseases
Protein degradation platforms — PROTAC protein degradation therapeutics